This provides a mechanistic explanation for the genetic association between a SNP in the SLAMF7 promoter and susceptibility to MS, and provides a foundation on which future studies aimed at modulating SLAM family receptors to treat autoimmune diseases may build from. This evidence concerns the gene SLAMF1 and myeloid sarcoma.